NINTH AMENDMENT AND WAIVERLoan Agreement • July 21st, 2023 • LumiraDx LTD • Pharmaceutical preparations • New York
This NINTH AMENDMENT AND WAIVER (this “Ninth Amendment”) is entered into as of July 20, 2023 (the “Ninth Amendment Effective Date”), by and among LumiraDx Investment Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 10260187 (the “Borrower”), LumiraDx Group Limited, a private company with limited liability incorporated under the laws of England and Wales with company number 09198288 (“Parent”), LumiraDx Limited, an exempted company incorporated with limited liability in the Cayman Islands (“Issuer”), the other Guarantors party thereto, as Credit Parties, BioPharma Credit PLC, a public limited company incorporated under the laws of England and Wales with company number 10443190, as collateral agent (in such capacity, the “Collateral Agent”) and BPCR Limited Partnership, a limited partnership established under the laws of England and Wales with registration number LP020944 (“BCPR”) and BioPharma Credit Investments V (Ma
